期刊文献+

血清miR-25与胃癌病理诊断和预后的相关性研究 被引量:1

Relativity study on serum miR-25 with pathology,diagnosis and prognosis of gastric cancer
下载PDF
导出
摘要 目的研究血清miR-25水平与胃癌(GC)患者的临床病理特征、诊断和预后之间的关系。方法对184例GC患者,56例胃炎患者和78名健康对照者的血清样本进行实时定量聚合酶链反应(RT-qPCR),探讨miR-25水平与GC临床病理特征(包括诊断和预后)的关系。结果与胃炎患者和健康人员相比,GC患者血清miR-25水平显著上调;以cutoff值0.042为标准,miR-25对GC患者的诊断敏感性为69.4%,特异性为80.4%;高血清miR-25水平与GC浸润深度和淋巴结转移相关,miR-25水平升高是患者预后不良的表现。结论血清miR-25水平是胃癌诊断和判断预后的一项可靠指标。 Objective To study the relationship between serum miR-25 levels and clinicopathological features,diagnosis and prognosis in patients with gastric cancer(GC). Methods Real-time quantitative polymerase chain reaction(RT-qPCR) was performed on serum samples from 184 patients with GC,among them 56 were of gastritis and 78 of healthy controls,and to investigate their relation between miR-25 levels and clinicopathological features (including diagnosis and prognosis). Results Compared with the patients with gastritis and healthy controls,serum miR-25 levels were significantly up-regulated with a cutoff value of 0.042 in the patients with GC. The diagnostic sensitivity of serum miR-25 to GC patients was 69.4%,specificity was 80.4%;high serum miR-25 levels were associated with GC infiltration depth and lymph node metastasis,and elevated serum miR-25 levels could prognose a poor outcome of patients. Conclusion Serum miR-25 level is a reliable indicator for diagnosing and judging prognosis of gastric cancer.
作者 毕书祝 杨越 牛平 王梅 BI Shu-zhu;YANG Yue;NIU Ping(Navy 92426 Troop Hospital,Internal Medcine,Qingdao,Shandong 266400,China)
出处 《实用医药杂志》 2019年第9期779-782,共4页 Practical Journal of Medicine & Pharmacy
关键词 胃癌 预后 诊断 血清miR-25 Gastric cancer Prognosis Diagnosis Clinical pathology Serum miR-25
  • 引文网络
  • 相关文献

参考文献1

二级参考文献20

  • 1Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225-262.
  • 2Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future, lnt J Biol Markers 2001; 16:73-86.
  • 3Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J lntern Med 2007; 18:175-184.
  • 4Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990; 77:961-962.
  • 5Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
  • 6Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
  • 7Chen C, Ridzon DA, Broomer A J, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
  • 8Tang F, Hajkova P, Barton SC, Lao K, Surani MA. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
  • 9Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3-12.
  • 10Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-2261.

共引文献984

同被引文献10

引证文献1

二级引证文献4

;
使用帮助 返回顶部